Biotia is a biotechnology company providing hospitals with tailored sequencing-based solutions to reduce hospital-acquired infections. Using sequencing and proprietary bioinformatics technology, we help hospitals to fight nosocomial infections and other diseases. Founded by Dr. O'Hara, Dr. Mason and Dr. Ounit, Biotia offers an active surveillance of the highest risk units, and incoming patients, and facilitating intervention before patients get sick.Diagnosing and researching infectious disease is challenging, with a high rate of diagnostic failure resulting in high mortality and alarming levels of drug resistance. Culturing, the current gold standard and technology from the 1800s, misses many important pathogens and requires many labor intensive tests. Even newer PCR-based tests are limited, problematic and don’t provide drug resistance information.We work with hospitals and researchers to leverage high-complexity tests and artificial intelligence for rapid precision infectious disease diagnostics to guide patient treatment and improve health outcomes. Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid precision infectious disease discovery. Our software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes.
B2B
1 to 25
Series A
$10.4 M
Scaling Up
2016
Healthcare
Health Care Facilities & Hospitals
Improve Health Outcomes
Leverage High-Complexity Tests
Increase Efficiency
Analytics
Service
Yes
Active
Machine Learning
Natural Language Processing
Software
NYS Lead Clinical Laboratory Technologist
Brooklyn, New York
Director of Sales and Business Development
New York, New York
AI/ML Professionals
11
1
$8M
Company was founded 2016 and it took almost 6 years (Aug 2022) to raise first external round
Investors
Interested in researching Biotia?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Biotia
